摘要
干扰素-λs(Interferon-λs,IFN-λs)是近年来发现的一类新型干扰素,由于其兼具I型干扰素和白细胞介素(interleukin,IL)-10家族的双重特征,因此其成员的命名为IFN-λ1(IL-29)、IFN-λ2(IL-28A)和IFN-λ3(IL-28B)。IFN-λs的受体隶属于II型细胞因子受体家族(classII cytokine receptor family,CRF2),由特有的配基结合亚基CRF2-12/IFN-λR1(又称IL-28Rα)和辅助亚基CRF2-4(IL-10R2)组成。IFN-λs与I型IFN相同,均可通过激活JAK-STAT(janus kinase-signal transducer and activator of transcription)信号通路来传递配基结合信号,因此IFN-λs显示了与IFN-α相似的抗病毒、抑制肿瘤细胞生长以及具免疫调节功能等生物学活性,但由于其骨髓抑制及毒副作用少而生物学作用具长效性,且临床试验研究已经取得了突破性进展,故有望在不久的将来成为一个新的基因工程药物。
IFN-λs（including IFN-λ1,IFN-λ2,and IFN-λ3）is a newly identified IFN family whose characters related to the type I IFNs and IL-10 family members.IFNλs act through a cell surface receptor composed of two chains,the first one （CRF2-12/IFN-λ R1/IL-28Rα） being IFN-λspecific and the second one （CRF2-4 /IL-10R2） shared with IL-10.IFN-λs signal through the IFN-λR1 and activate JAK-STATs pathways,as well as type I IFNs.So,IFN-λs exhibit several common features with type I IFNs：antiviral activity,antiproliferative activity and in vivo antitumour activity.And most importantly,clinical trialsⅠwith PEG-IFN-λ1was completed as a novel medicine to HCV.The latest research progress about the biology of IFN-λs were reviewed and the application of IFN-λs may to the clinical medicine in the near future was pointed.
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2010年第4期95-100,共6页
China Biotechnology
基金
国家自然科学基金资助项目(30470896)
